Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

MULTIPLE SCLEROSIS

Disease-modifying therapy aids cognition in multiple sclerosis

A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive benefits; however, limitations of the original studies, including brief duration, restricted assessment and failure to account for baseline cognitive impairment, might limit the interpretation of the findings.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Benedict, R. H. & Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 7, 332–342 (2011).

    Article  Google Scholar 

  2. Amato, M. P., Krupp, L. B., Charvet, L. E., Penner, I. & Till, C. Pediatric multiple sclerosis: cognition and mood. Neurology 87, S82–S87 (2016).

    Article  Google Scholar 

  3. Sotirchos, E. S. et al. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Mult. Scler. 26, 312–321 (2020).

    CAS  Article  Google Scholar 

  4. Amato, M. P. et al. Association of neocortical volume changes with cognitive deterioration in relapsing–remitting multiple sclerosis. Arch. Neurol. 64, 1157–1161 (2007).

    Article  Google Scholar 

  5. Landmeyer, N. C. et al. Disease-modifying treatments and cognition in relapsing–remitting multiple sclerosis: a meta-analysis. Neurology 94, e2373–e2383 (2020).

    CAS  Article  Google Scholar 

  6. Kalb, R. et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult. Scler. 13, 1665–1680 (2018).

    Article  Google Scholar 

  7. Rocca, M. A. et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 14, 302–317 (2015).

    Article  Google Scholar 

  8. Montalban, X. et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96–120 (2018).

    Article  Google Scholar 

  9. Rae-Grant, A. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis — report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90, 777–788 (2018).

    Article  Google Scholar 

  10. Trojano, M. et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies. Nat. Rev. Neurol. 13, 105–118 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria Pia Amato.

Ethics declarations

Competing interests

M.P.A. has received research grants from Biogen, Merck, Teva, Roche, Novartis and Sanofi Genzyme and honoraria as a speaker and advisory board member from Biogen, Merck, Teva, Roche, Novartis and Sanofi Genzyme. L.B.K. has received consulting fees, served on data and safety monitoring boards or received grant support from Biogen, Novartis, Sanofi and Genzyme, and has received licensing fees from various pharmaceutical and biomedical companies for the Fatigue Severity Scale.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Amato, M.P., Krupp, L.B. Disease-modifying therapy aids cognition in multiple sclerosis. Nat Rev Neurol 16, 525–526 (2020). https://doi.org/10.1038/s41582-020-0383-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-020-0383-x

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing